Effects of Dapagliflozin in Patients With Membranous Nephropathy.pptx

dapa in MN

1. Heerspink HJ, Wheeler DC, Correa-Rotter R, Dwyer JP, Langkilde AM, Mark PB, Nowicki M, Rossing P, Toto RD, Chertow GM, Jongs N. WCN24-1766 EFFECTS OF DAPAGLIFLOZIN IN PATIENTS WITH MEMBRANOUS NEPHROPATHY. Kidney International Reports. 2024 Apr 1;9(4):S173.

2. Membranous nephropathy is the most common cause of primary nephrotic syndrome in adults worldwide. This analysis assessed the safety and efficacy of dapagliflozin in patients with membranous nephropathy enrolled in the DAPA-CKD trial. Introduction Kidney International Reports. 2024 Apr 1;9(4):S173.

3. Baseline characteristics of patients in DAPA-CKD with membranous nephropathy. Kidney International Reports. 2024 Apr 1;9(4):S173.

4. Results